Indegene Q2 FY27 Revenue Rises 39.6% to ₹1,122 Crore

Indegene Limited reported consolidated revenue from operations of ₹1,122.3 crore for the quarter ended 30 September 2026, marking year-on-year growth of 39.6%. Revenue in the corresponding quarter of the previous year stood at ₹804.2 crore. Profit after tax rose 10.0% year on year to ₹112.3 crore from ₹102.1 crore. The results place focus on the company’s commercial solutions business, which remained the larger contributor to quarterly revenue. The board was scheduled to consider the unaudited standalone and consolidated results on 29 October 2026.

Revenue growth continues into the second quarter

The September-quarter performance followed consolidated revenue of ₹1,063.1 crore in the June 2026 quarter. This means revenue increased by about ₹59.2 crore sequentially from Q1 FY27. In Q1 FY27, revenue had risen 39.7% year on year from ₹761 crore. The latest quarter therefore extended the company’s strong top-line growth trajectory into the first half of FY27. The reported figures reflect continued execution in life sciences digital commercialisation engagements.

Profit growth trails the top line

Profit after tax for Q2 FY27 was ₹112.3 crore, compared with ₹102.1 crore a year earlier. Basic earnings per share increased to ₹4.67 from ₹4.26 in Q2 FY26. While revenue grew by 39.6%, profit after tax grew at a slower 10.0% rate. This difference is relevant for investors assessing how revenue expansion is translating into earnings. The company’s reported Q2 figures provide the latest basis for evaluating that relationship.

Commercial solutions remain the largest segment

Enterprise Commercial Solutions contributed ₹800.2 crore in revenue during Q2 FY27. The segment accounted for the larger share of the company’s reported revenue base. Segment result for Enterprise Commercial Solutions rose to ₹130.2 crore from ₹98.2 crore in the year-ago quarter. The increase indicates that the commercial business was a key contributor to Indegene’s quarterly growth. Enterprise Medical Solutions also recorded year-on-year expansion during the period.

Medical solutions show a measured increase

Enterprise Medical Solutions reported a segment result of ₹62.6 crore in Q2 FY27, compared with ₹57.5 crore in Q2 FY26. The segment’s result increased by ₹5.1 crore from the comparable quarter. Indegene operates through Enterprise Medical Solutions and Enterprise Commercial Solutions as its two primary reportable segments. Together, these segments form the core of the company’s reported operating structure. The segment disclosures help show where the company’s quarterly performance was generated.

Recent quarterly trend provides context

Indegene’s consolidated revenue has increased across the last four reported quarters in the available data. Revenue rose from ₹804 crore in September 2025 to ₹942 crore in December 2025, ₹1,003 crore in March 2026 and ₹1,063 crore in June 2026. Operating profit was ₹130 crore in the June 2026 quarter, with an operating profit margin of 12.2%. Net profit in that quarter was ₹116 crore, while earnings per share stood at ₹4.84. These figures provide context ahead of a fuller discussion of the September-quarter performance.

Operating cash flow is an additional data point

The supplied half-year data shows net cash generated from operating activities of negative ₹13.3 crore for the six months ended 30 September 2026. This compares with positive ₹202.8 crore in the prior-year half. The contrast between revenue growth and operating cash flow is a notable part of the reported financial information. Revenue rose strongly in Q2 FY27, but the half-year operating cash-flow figure moved into negative territory. The available information does not specify the underlying reasons for this movement.

Board approval and auditor review

The board meeting notice said directors would consider unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. It also covered the limited review report from the auditors. The reported information states that the board approved the results and that the limited review opinions were unmodified. The meeting agenda also included allotments under the RSU Scheme 2020 and ESOP Scheme 2020. The filing noted that the trading window had been closed in line with insider-trading compliance requirements.

Earnings call scheduled for 30 October

Indegene has scheduled its Q2 FY27 earnings call for 30 October 2026 at 8:00 AM IST. Chairman and CEO Manish Gupta and CFO Suhas Prabhu were named in the call intimation. The call is expected to provide management commentary on the September-quarter numbers and the first-half performance. Investors will also be able to assess any discussion around segment execution, profitability and cash generation. The board-result announcement and earnings call are the next confirmed events associated with the company’s quarterly disclosure cycle.

What the results mean for investors

The Q2 FY27 numbers show continued revenue momentum, led by the Enterprise Commercial Solutions segment. Revenue growth of 39.6% extended the expansion seen in the June quarter. However, the 10.0% rise in profit after tax and the negative half-year operating cash flow add further financial measures for investors to monitor. The scheduled earnings call on 30 October 2026 is the next opportunity for management to address the reported quarter and half-year data.